Dare Bioscience (Dare Bioscience) EBIT per Share : $-0.32 (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Dare Bioscience EBIT per Share?

Dare Bioscience's EBIT per Share for the three months ended in Mar. 2024 was $-0.06. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.32.

During the past 3 years, the average EBIT per Share Growth Rate was 27.00% per year. During the past 5 years, the average EBIT per Share Growth Rate was 22.00% per year. During the past 10 years, the average EBIT per Share Growth Rate was 30.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Dare Bioscience's EBIT per Share or its related term are showing as below:

DARE' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -6.8 Med: 27 Max: 62.3
Current: 27

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Dare Bioscience was 62.30% per year. The lowest was -6.80% per year. And the median was 27.00% per year.

DARE's 3-Year EBIT Growth Rate is ranked better than
78.53% of 1304 companies
in the Biotechnology industry
Industry Median: 3.6 vs DARE: 27.00

Dare Bioscience's EBIT for the three months ended in Mar. 2024 was $-6.02 Mil.

Dare Bioscience EBIT per Share Historical Data

The historical data trend for Dare Bioscience's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dare Bioscience EBIT per Share Chart

Dare Bioscience Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.92

-0.91

-0.64

-0.37

-0.35

Dare Bioscience Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.10	-0.10	-0.09	-0.06	-0.06

Dare Bioscience EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Dare Bioscience's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-30.94	/	87.304
=	-0.35

Dare Bioscience's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.022	/	100.514
=	-0.06

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.32

Dare Bioscience (NAS:DARE) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Dare Bioscience EBIT per Share Related Terms

Thank you for viewing the detailed overview of Dare Bioscience's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Dare Bioscience (Dare Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dare Bioscience Inc (NAS:DARE) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

3655 Nobel Drive, Suite 260, San Diego, CA, USA, 92122

Website

https://www.darebioscience.com

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Executives

Sophia Nnenna Ononye-onyia	director	1270 AVE OF THE AMERICAS, 7TH FL - 1026, NEW YORK NY 10020
Sabrina Martucci Johnson	director, officer: Chef Executive Officer	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
John A Fair	officer: Chief Strategy Officer	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Cheryl R Blanchard	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Roger Hawley	director	3655 NOBEL DRIVE, SUITE 260, SAN DIEGO CA 92122
Gregory W Matz	director	1 WHITE OAK WAY, NOVATO CA 94949
Jessica D. Grossman	director	C/O DARE BIOSCIENCE, INC., 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Lisa Walters-hoffert	officer: Chief Financial Officer	C/O DARE BIOSCIENCE, INC., 10210 CAMPUS POINT DRIVE, SUITE 150, SAN DIEGO CA 92121
Robin Joan Steele	director	3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Scott Eliasof	officer: SVP, Chief Scientific Officer	C/O CERULEAN PHARMA INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
David R Walt	director	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Adrian Senderowicz	officer: SVP, Chief Medical Officer	C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Stuart A Arbuckle	director	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Alejandra Carvajal	officer: VP, General Counsel	C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
James E Oneill	officer: Principal Accounting Officer	15 GREENBRIAR CIRCLE, ANDOVER MA 01810